Ameriprise Financial Inc. decreased its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 20.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 374,610 shares of the biopharmaceutical company’s stock after selling 96,131 shares during the quarter. Ameriprise Financial Inc. owned 0.36% of Juno Therapeutics worth $11,198,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. M&T Bank Corp bought a new position in shares of Juno Therapeutics during the 1st quarter worth about $381,000. Laurion Capital Management LP bought a new position in shares of Juno Therapeutics during the 1st quarter worth about $390,000. Marshall Wace LLP bought a new position in shares of Juno Therapeutics during the 2nd quarter worth about $1,071,000. Geode Capital Management LLC increased its holdings in shares of Juno Therapeutics by 8.9% during the 1st quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock worth $13,206,000 after purchasing an additional 48,516 shares during the period. Finally, Brighton Jones LLC bought a new position in shares of Juno Therapeutics during the 2nd quarter worth about $260,000. Institutional investors own 67.38% of the company’s stock.
In other Juno Therapeutics news, EVP Robert Azelby sold 12,850 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total value of $577,607.50. Following the transaction, the executive vice president now directly owns 37,439 shares of the company’s stock, valued at approximately $1,682,883.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,085,004 shares of company stock worth $219,551,561. Insiders own 15.26% of the company’s stock.
JUNO has been the topic of several research reports. Vetr downgraded shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $27.60 price objective on the stock. in a report on Tuesday, June 20th. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Zacks Investment Research upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Tuesday, July 11th. Maxim Group restated a “buy” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday. Finally, Morgan Stanley boosted their price objective on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, August 7th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Juno Therapeutics has an average rating of “Hold” and an average price target of $37.83.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/11/ameriprise-financial-inc-reduces-stake-in-juno-therapeutics-inc-juno.html.
Shares of Juno Therapeutics, Inc. (JUNO) opened at 43.19 on Wednesday. The company has a 50-day moving average of $41.59 and a 200-day moving average of $29.86. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $47.03. The company’s market cap is $4.53 billion.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the prior year, the business earned ($0.64) earnings per share. Juno Therapeutics’s quarterly revenue was down 22.8% compared to the same quarter last year. Equities analysts forecast that Juno Therapeutics, Inc. will post ($3.12) EPS for the current year.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.